Published March 2019
| Version v1
Journal article
Moderate Hypofractionation in Intermediate- and High-Risk, Localized Prostate Cancer: Health-Related Quality of Life From the Randomized, Phase 3 HYPRO Trial
Creators
- 1. Department of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam (Netherlands)
- 2. Department of Radiation Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam (Netherlands)
Description
The phase 3 Hypofractionated Irradiation for Prostate Cancer trial compared hypofractionated radiation therapy with conventionally fractionated radiation therapy in patients with localized prostate cancer. Similar 5-year relapse-free survival rates were achieved in both groups, but noninferiority of hypofractionation was not confirmed for genitourinary and gastrointestinal toxicity. Here, we present the secondary trial endpoint on patient-reported quality of life.
Additional details
Identifiers
- DOI
- 10.1016/j.ijrobp.2018.11.020;
- PII
- S0360301618340069;
Publishing Information
- Journal Title
- International Journal of Radiation Oncology, Biology and Physics
- Journal Volume
- 103
- Journal Issue
- 4
- Journal Page Range
- p. 823-833
- ISSN
- 0360-3016
- CODEN
- IOBPD3
INIS
- Country of Publication
- United States
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 55057248
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- FRACTIONATED IRRADIATION; NEOPLASMS; PATIENTS; PROSTATE; QUALITY OF LIFE; RADIOTHERAPY; TOXICITY
- Descriptors DEC
- BODY; DISEASES; GLANDS; IRRADIATION; MALE GENITALS; MEDICINE; NUCLEAR MEDICINE; ORGANS; RADIOLOGY; THERAPY
Optional Information
- Copyright
- Copyright (c) 2018 Elsevier Inc. All rights reserved.